• LB Pharmaceuticals posted a net loss of $19.1 million for first-quarter 2026, widening from $5.3 million a year earlier, as operating loss deepened to $22.1 million from $6.43 million.
• R&D expense climbed to $14.6 million from $3.4 million, due to higher clinical trial costs tied to LB-102 studies in bipolar 1 depression and acute schizophrenia, alongside higher production and personnel spending.
• G&A expense rose to $7.5 million from $3 million, driven by higher headcount, stock-based compensation, and professional fees.
• Cash, cash equivalents, and marketable securities increased to $365.6 million as of March 31, 2026, with runway expected into Q2 2029.
• Initiated Phase 3 NOVA-2 in schizophrenia with topline data expected in second-half 2027, started Phase 2 ILLUMINATE-1 in bipolar 1 depression with data expected in Q1 2028, and reiterated plans to begin a Phase 2 adjunctive MDD trial in early 2027 with data expected in first-half 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121605PRIMZONEFULLFEED9716701) on May 12, 2026, and is solely responsible for the information contained therein.